MondegarAI
Exome Asset Management LLC

Q1 2026 · 13F-HR

Exome Asset Management LLCholdings as filed

Filed 2026-05-15 · accession 0001420506-26-001033

$193.3M
Reported value
56
Positions
2026-03-31
Period end
View analyzed profile →PRO

The Brief · Exome Asset Management LLC · Q1 2026

AI · grounded in 13F

Exome Asset Management LLC closed its position in WVE for a reduction of $7.17M. The fund established new positions in XBI for $7.66M, INSM for $4.36M, and MLTX for $4.01M. Other notable exits included closing positions in AZNN and JAZZ.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
74006W207PRAXPRAXIS PRECISION MEDICINES I$14.6M7.58%45,469CommonSOLE
19240Q201COGTCOGENT BIOSCIENCES INC$10.7M5.54%278,533CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$8.6M4.46%220,091CommonSOLE
462222100IONSIONIS PHARMACEUTICALS INC$8.3M4.27%110,064CommonSOLE
78464A870XBISPDR SERIES TRUST$7.7M3.96%60,000PUTSOLE
40131M109GHGUARDANT HEALTH INC$7.6M3.95%82,736CommonSOLE
23282W605CYTKCYTOKINETICS INC$6.8M3.54%103,718CommonSOLE
532457108LLYELI LILLY & CO$6.4M3.34%7,012CommonSOLE
022307102ALMSALUMIS INC$6.2M3.18%279,176CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$5.0M2.59%67,492CommonSOLE
92337R101VERAVERA THERAPEUTICS INC$4.6M2.39%114,991CommonSOLE
457669307INSMINSMED INC$4.4M2.25%26,651CommonSOLE
036752103ELVELEVANCE HEALTH INC FORMERLY$4.3M2.22%14,677CommonSOLE
00847X104AGIOAGIOS PHARMACEUTICALS INC$4.2M2.19%125,060CommonSOLE
91307C102UTHRUNITED THERAPEUTICS CORP DEL$4.2M2.16%7,053CommonSOLE
61559X104MLTXMOONLAKE IMMUNOTHERAPEUTICS$4.0M2.08%215,376CommonSOLE
23282W955CYTKCYTOKINETICS INC$4.0M2.05%60,000PUTSOLE
632307104NTRANATERA INC$3.7M1.93%18,650CommonSOLE
76243J105RYTMRHYTHM PHARMACEUTICALS INC$3.5M1.83%40,581CommonSOLE
91324P102UNHUNITEDHEALTH GROUP INC$3.5M1.80%12,862CommonSOLE
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$3.4M1.78%85,517CommonSOLE
92337C203VSTMVERASTEM INC$3.4M1.75%636,700CommonSOLE
88025U109TXG10X GENOMICS INC$3.3M1.69%154,194CommonSOLE
101137107BSXBOSTON SCIENTIFIC CORP$3.0M1.57%48,347CommonSOLE
G01767105ALKSALKERMES PLC$3.0M1.54%84,103CommonSOLE
07725L902ONCBEONE MEDICINES LTD$3.0M1.54%10,000CALLSOLE
61225M102GLUEMONTE ROSA THERAPEUTICS INC$3.0M1.53%179,484CommonSOLE
46120E602ISRGINTUITIVE SURGICAL INC$2.9M1.52%6,358CommonSOLE
005329107ADAGADAGENE INC$2.9M1.49%736,845CommonSOLE
04280A100ARWRARROWHEAD PHARMACEUTICALS IN$2.9M1.48%45,721CommonSOLE
G2545C104CBIOCRESCENT BIOPHARMA INC.$2.8M1.46%153,191CommonSOLE
75943R102RLAYRELAY THERAPEUTICS INC$2.8M1.43%278,302CommonSOLE
578784100MAZEMAZE THERAPEUTICS INC$2.6M1.37%88,510CommonSOLE
23284F105CTMXCYTOMX THERAPEUTICS INC.$2.5M1.27%521,468CommonSOLE
05338F306AVTXAVALO THERAPEUTICS INC$2.4M1.23%159,341CommonSOLE
022307952ALMSALUMIS INC$2.3M1.20%105,000PUTSOLE
377322102GKOSGLAUKOS CORP$2.2M1.16%20,874CommonSOLE
21833P301CRBPCORBUS PHARMACEUTICALS HLDGS$2.2M1.14%234,136CommonSOLE
70975L107PENPENUMBRA INC$2.1M1.07%6,300CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$2.1M1.07%61,673CommonSOLE
53635D202LQDALIQUIDIA CORPORATION$1.7M0.89%45,796CommonSOLE
98937L105ZBIOZENAS BIOPHARMA INC$1.6M0.82%80,730CommonSOLE
53635D952LQDALIQUIDIA CORPORATION$1.5M0.78%40,000PUTSOLE
44975P103NBPNOVABRIDGE BIOSCIENCES$1.4M0.73%576,960CommonSOLE
152309950CNTACENTESSA PHARMACEUTICALS PLC$1.4M0.71%34,700PUTSOLE
45166A902IDYAIDEAYA BIOSCIENCES INC$1.3M0.69%40,000PUTSOLE
45166A902IDYAIDEAYA BIOSCIENCES INC$1.3M0.69%40,000CALLSOLE
35104E100FDMT4D MOLECULAR THERAPEUTICS IN$1.2M0.63%130,564CommonSOLE
65343E207NXTCNEXTCURE INC$1.2M0.63%115,500CommonSOLE
696389402PALIPALISADE BIO INC$1.1M0.54%600,000CommonSOLE
G31249108ESTAESTABLISHMENT LABS HLDGS INC$743,8180.38%13,100CommonSOLE
89422G957TVTXTRAVERE THERAPEUTICS INC$594,2000.31%20,000PUTSOLE
53630X203LPCNLIPOCINE INC NEW$486,2790.25%60,861CommonSOLE
03879J100ABUSARBUTUS BIOPHARMA CORP$339,6780.18%75,484CommonSOLE
Y95308955WVEWAVE LIFE SCIENCES LTD$217,5000.11%30,000PUTSOLE
20454B904CMPXCOMPASS THERAPEUTICS INC$132,7790.07%25,100CALLSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.